PM&R
Volume 1, Issue 9 , Pages 839-841 , September 2009

Role of Oral Medications in Spasticity Management

Received 15 July 2009 ,Accepted 30 July 2009.

References 

  1. Sieghart W. Pharmacology of benzodiazepine receptors: An update. J Psychiatry Neurosc. 1994;19:24–29
  2. Verrer M, MacLeod S, Ashby P. The effects of diazepam on presynaptic inhibition in patients with complete and incomplete spinal cord injuries. Can J Neurol Sci. 1975;2:179–184
  3. Corbett M, Frnkel HL, Michaelis L. A double-blind, cross-over trial of Valium in the treatment of spasticity. Paraplegia. 1972;10:19–22
  4. Graoves L, Shellenberger MK, Davis CS. Tizanadine treatment of spasticity: A meta-analysis of controlled, double-blind, comparative studies with baclofen and diazepam. Adv Ther. 1998;15:241–251
  5. Duncan GW, Shahani BT, Young RR. An evaluation of baclofen treatment for certain symptoms in patients with spinal cord lesions. Neurology. 1976;26:441–446
  6. Brar SP, Smith MB, Nelson LM, Franklin GM, Cobble ND. Evaluation of treatment protocols on minimal to moderate spasticity in multiple sclerosis. Arch Phys Med Rehabil. 1991;72:186–189
  7. Wallace AE, Kline AE, Montanez S, Hernandez TD. Impact of the novel anti-convulsant vigabatrin on functional recovery following brain lesion. Restor Neurol Neurosci. 1999;14:35–45
  8. Allerton CA, Boden PR, Hill RG. Actions of the GABAB agonist(-)-baclofen on neurons in deep dorsal horn of the rat spinal cord in vitro. Br J Pharmacol. 1989;96:29–38
  9. Hulme A, MacLennan WJ, Ritchie RT, John VA, Shotton PA. Baclofen in the elderly sroke patient: Its side effects and pharmacokinetics. Eur J Clin Pharmacol. 1985;29:467–469
  10. Donovan WH, Carter RE, Rossi CD, Wilkerson MA. Clonidine effect of spasticity: A clinical trial. Arch Phys Med Rehabil. 1988;69:193–194
  11. Goldstein LB. Potential effects of common drugs on stroke recovery. Arch Neurol. 1998;55:454–456
  12. Malanga G, Reiter RD, Garay E. Update on tizanidine for muscle spasticity and emerging indications. Exp Opin Pharmacother. 2008;9:2209–2215
  13. Meythaler JM, Guin-Renfroe S, Johnson A, Brunner RM. Prospective assessment of tizanidine for spasticity due to acquired brain injury. Arch Phys Med Rehabil. 2001;82:1155–1163
  14. Gelber DA, Good DC, Dromerick A, Sergay S, Richardson M. Open-label dose-titration safety and efficacy study of tizanidine hydrochloride in the treatment of spasticity associated with chronic stroke. Stroke. 2001;32:1841–1846
  15. Ward A, Chaffman MO, Sorkin EM. Dantrolene (A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in malignant hyperthermia, the neuroleptic malignant syndrome and an update of its use in muscle spasticity). Drugs. 1986;32:130–168
  16. Katrak PH, Cole AM, Poulos CJ, McCauley JC. Objective assessment of spasticity, strength and function with early exhibition of dantrolene sodium after cerebrovascular accident: A randomized double-blind study. Arch Phys Med Rehabil. 1992;73:4–9
  17. Nance P. A comparison of clonidine, cyproheptadine and baclofen in spastic spinal cord injured patients. J Am Paraplegia Soc. 1994;17:151–157
  18. Collin C, Davies P, Mutiboko IK, Ratcliffe S Sativex Spasticity in MS study group. Randomized controlled trial of cannabis-based medicine in spasticity caused by multiple sclerosis. Eur J Neurol. 2007;14:290–296
  19. Hansebout RR, Blight AR, Fawcett S, Reddy K. 4-Aminopyridine in chronic spinal cord injury: a controlled, double-blind, crossover study in eight patients. J Neurotrauma. 1993;10:1–18
  20. Cardenas DD, Graziani V, Jackson A, et al. Phase 2 trial of sustained-release fampridine in chronic spinal cord injury. Spinal Cord. 2007;45:158–168
  21. Bradley LJ, Kirker SGB. Pregabalin in the treatment of spasticity: A retrospective case series. Disability Rehabil. 2008;30:1230–1232
  22. Mueller ME, Gruenthal M, Olson WL, Olson WH. Gabapentin for relief of upper motor neuron symptoms in multiple sclerosis. Arch Phys Med Rehabil. 1997;78:521–524
  23. Montane E, Vallano A, Laporte JR. Oral antispastic drugs in nonprogressive neurological diseases. Neurology. 2004;63:1357–1363
  24. Elovic EP, Esquenazi A, Alter KE, Lin JL, Alfaro A, Kaelin DL. Chemodenervation and nerve blocks in the diagnosis and management of spasticity and muscle overactivity. PMR&R. 2009;1:842–851

 Disclosure Key can be found on the Table of Contents and at www.pmrjournal.org

PII: S1934-1482(09)00759-X

doi: 10.1016/j.pmrj.2009.07.014

PM&R
Volume 1, Issue 9 , Pages 839-841 , September 2009

Article Tools